Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Super Micro Computer rises sharply, Nvidia sells its stake in SoundHound, Airbnb swings to a profit in the fourth quarter, and Moderna posts a wider-than-expected quarterly loss.
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna shares fell after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2.91 per share, ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results